RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25). The high-profile conference will take place in Chicago from March 29 to March 31, 2025.
The trial focuses on evaluating the efficacy and safety of lorundrostat, a novel aldosterone synthase inhibitor, for the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). These conditions remain a significant challenge for patients and healthcare providers, emphasizing the importance of innovative therapeutic developments like lorundrostat.
The study’s presentation will be delivered by Luke Laffin of the Cleveland Clinic Foundation, representing the Advance-HTN investigators. Details for the session include:
- Abstract Title: Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, in Patients With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
- Presenter: Luke Laffin, Advance-HTN Investigators, Cleveland Clinic Foundation
- Session Date/Time: Saturday, March 29, from 1:45 p.m. to 1:55 p.m. CT
- Session Title: Late-Breaking Clinical Trials III (Session 104)
- Session Location: Main Tent, North Hall B
The scheduled presentation of this data at ACC.25 underscores its potential impact within the field of cardiovascular medicine. Lorundrostat’s performance in addressing tough-to-treat hypertension could pave the way for new standard-of-care solutions.
This represents a significant milestone for Mineralys Therapeutics as it works to bring innovative therapies to the hypertension market, addressing a critical and underserved medical need.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.